CoChat

Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting

Open access
Julian, Cristina, Pal, Navdeep, Gershon, Anda, Evangelista, Marie, Purkey, Hans, Lambert, Peter, Shi, Zhen, Zhang, Qing · 2023 · BMC Cancer

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Background: KRAS mutations occur frequently in advanced non-small cell lung cancer (aNSCLC); the G12C mutation is the most prevalent. Alterations in STK11 or KEAP1 commonly co-occur with KRAS mutations in aNSCLC. Using real-world data, we assessed the effect of KRAS G12C mutation with or without STK11 and/or KEAP1 mutations on overall survival (OS) in patients with aNSCLC receiving cancer immunotherapy (CIT), chemotherapy, or both in first line (1L) and second line (2L). Methods: Patients diagnosed with aNSCLC between January 2011 and March 2020 in a clinico-genomic database were included. Cox proportional hazards models adjusted for left truncation, baseline demographics and clinical characteristics were used to analyze the effect of STK11 and/or KEAP1 co-mutational status on OS in patients with KRAS wild-type (WT) or G12C mutation. Results: Of 2715 patients with aNSCLC without other actionable driver mutations, 1344 (49.5%) had KRAS WT cancer, and 454 (16.7%) had KRAS G12C– positive cancer. At 1L treatment start, significantly more patients with KRAS G12C –positive cancer were female, smokers, and had non-squamous histology, a higher prevalence of metastasis and programmed death-ligand 1 positivity than those with KRAS WT cancer. Median OS was comparable between patients with KRAS G12C– positive and KRAS WT cancer when receiving chemotherapy or combination CIT and chemotherapy in the 1L or 2L. Median OS was numerically longer in patients with KRAS G12C vs KRAS WT cancer treated with 1L CIT (30.2 vs 10.6 months, respectively) or 2L CIT (11.3 vs 7.6 months, respectively). Co-mutation of STK11 and KEAP1 was associated with significantly shorter OS in patients receiving any type of 1L therapy, regardless of KRAS G12C mutational status. Conclusions: This real-world study showed that patients with KRAS G12C– positive or KRAS WT cancer have similar OS in the 1L or 2L when treated with chemotherapy or combination CIT and chemotherapy. In contrast to aNSCLC patients with EGFR or ALK driver mutations, patients with KRAS G12C– positive cancer may benefit from CIT monotherapy. Co-mutation of STK11 and KEAP1 was associated with significantly shorter survival, independent of KRAS G12C mutational status, reflecting the poor prognosis and high unmet need in this patient population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-023-10778-6

Cites

Statistics

Figures

Fig. 1 KRAS Mutational Status in (A) the 1L and (B) the 2L Settings. SV, short variant; WT, wild type
Fig. 1 KRAS Mutational Status in (A) the 1L and (B) the 2L Settings. SV, short variant; WT, wild typeCC BY · PubMed Central
Fig. 2 Prevalence of Metastasis in Patients With aNSCLC Treated in the 1L. 1L, first line; aNSCLC, advanced non-small cell lung cancer; WT, wild type
Fig. 2 Prevalence of Metastasis in Patients With aNSCLC Treated in the 1L. 1L, first line; aNSCLC, advanced non-small cell lung cancer; WT, wild typeCC BY · PubMed Central
Fig. 3 KRAS Mutational Status on OS by Treatment in (A) the 1L* and (B) the 2L†. 1L, first line; 2L, second line; aHR, adjusted hazard ratio; CIT, cancer immunotherapy; ns, non-significant; OS, overall survival; PD-L1, programmed cell death 1 ligand 1; TMB, tumor mutational burden; WT, wild type. * n = 1798; adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, and histology in the 1L. † n = 1016; adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, histology, and drug category in the 1L
Fig. 3 KRAS Mutational Status on OS by Treatment in (A) the 1L* and (B) the 2L†. 1L, first line; 2L, second line; aHR, adjusted hazard ratio; CIT, cancer immunotherapy; ns, non-significant; OS, overall survival; PD-L1, programmed cell death 1 ligand 1; TMB, tumor mutational burden; WT, wild type. * n = 1798; adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, and histology in the 1L. † n = 1016; adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, histology, and drug category in the 1LCC BY · PubMed Central
Fig. 4 Effect of STK11 and/or- KEAP1 Mutations on OS in Patients With aNSCLC in the 1L* With (A) KRAS WT or (B) KRAS G12C and in the 2L† With (C) KRAS WT or (D) KRAS G12C. 1L, first line; 2L, second line; aHR, adjusted hazard ratio; aNSCLC, advanced non-small cell lung cancer; ns, non-significant; OS, overall survival; PD-L1, programmed cell death 1 ligand 1; TMB, tumor mutational burden; WT, wildtype. * Adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, and histology. † Adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, histology, and drug category in the 1L. ‡ HR comparing STK11 WT-KEAP1 WT vs mSTK11 and/or mKEAP1
Fig. 4 Effect of STK11 and/or- KEAP1 Mutations on OS in Patients With aNSCLC in the 1L* With (A) KRAS WT or (B) KRAS G12C and in the 2L† With (C) KRAS WT or (D) KRAS G12C. 1L, first line; 2L, second line; aHR, adjusted hazard ratio; aNSCLC, advanced non-small cell lung cancer; ns, non-significant; OS, overall survival; PD-L1, programmed cell death 1 ligand 1; TMB, tumor mutational burden; WT, wildtype. * Adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, and histology. † Adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, histology, and drug category in the 1L. ‡ HR comparing STK11 WT-KEAP1 WT vs mSTK11 and/or mKEAP1CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 34 · Cited by 31

Research works printed but not linked: 1

  1. Cho BC, Lopes G, Kowalski DM, Kasahara K, editors. Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC. American Association for Cancer Research Virtual Annual Meeting II; 2020.

Metadata

Authors
Julian, C., Pal, N., Gershon, A., Evangelista, M., Purkey, H., Lambert, P., Shi, Z., & Zhang, Q.
Affiliations
Genentech (US)
Corresponding author
  • Shi, Zhen
  • Zhang, Qing
Venue
BMC Cancer
Published
2023-04-17
Volume
23
Issue
1
Pages
352-352
ISSN
1471-2407 (ISSN-L)
OpenAlex
W4366179288
Cited by
31
References
34
Citations by year
2026: 11 · 2025: 10 · 2024: 10
FWCI
5.71
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • F. Hoffmann-La Roche
  • Genentech
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
advanced non-small cell lung cancer, KRAS G12C mutation, STK11 mutation, KEAP1 mutation, co-occurring mutations, overall survival, cancer immunotherapy, chemotherapy, first-line therapy, second-line therapy, real-world data, driver mutations, PD-L1 expression, smoking status, histology, metastasis, progression-free survival, treatment-related adverse events
MeSH terms
Kelch-Like ECH-Associated Protein 1, AMP-Activated Protein Kinase Kinases, Adolescent, Adult, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Mutation, Survival Rate, Proto-Oncogene Proteins p21(ras), Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting. https://app.cochat.ai/papers/10.1186/s12885-023-10778-6
The paper
Julian, C., Pal, N., Gershon, A., Evangelista, M., Purkey, H., Lambert, P., Shi, Z., & Zhang, Q. (2023). Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting. BMC Cancer. https://doi.org/10.1186/s12885-023-10778-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.